Unique ID issued by UMIN | UMIN000048456 |
---|---|
Receipt number | R000055216 |
Scientific Title | Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study |
Date of disclosure of the study information | 2023/11/28 |
Last modified on | 2023/11/28 14:10:48 |
Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects
Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects
Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects
Japan |
Healthy Japanese subjects
Not applicable | Adult |
Others
NO
To verify the effects of consumption of the food containing lactic acid bacteria on the intestinal environment in healthy Japanese subjects
Efficacy
Confirmatory
Pragmatic
Not applicable
1. Gut microbiota
1. The state of defecation (numbers of defecation days, defecation frequency, amount of defecation, stool shape, stool color, stool smell, and exhilarating feeling of defecation)
2. Organic acids and intestinal putrefactive products
3. The Japanese Version of the Constipation Assessment Scale Middle Term version (CAS-MT)
4. OSA sleep inventory MA version
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
Institution is not considered as adjustment factor.
YES
2
Treatment
Food |
Duration: Two weeks
Test food: Tablet containing lactic acid bacteria
Administration: Take one tablet with water at any time during the day
*Daily dose should be taken within the day and not carried over to the next day.
Duration: Two weeks
Test food: Tablet not containing lactic acid bacteria
Administration: Take one tablet with water at any time during the day
*Daily dose should be taken within the day and not carried over to the next day.
20 | years-old | <= |
64 | years-old | >= |
Male and Female
1. Japanese
2. Men or women
3. Subjects aged between 20 and 64
4. Healthy subjects
5. Subjects whose defecation frequency is three to five times per week
6. Subjects whose occupancy rate of Bifidobacterium is relatively low
Subjects (who/whose)
1.are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2.have a pacemaker or an implantable cardioverter defibrillator (ICD)
3.currently undergoing treatment for chronic disease such as arrhythmia, hepatopathy, nephropathy, cerebrovascular disorder, rheumatism, diabetes, dyslipidemia, hypertension
4.have chronic constipation
5.have other diseases that may significantly affect bowel movement, or who have a medical history of them
6.have asthma, or may develop asthma during this trial
7.occupancy rate of Lactobacillales order or Bifidobacterium at screening (before consumprion; Scr) is 0%
8.usually use foods containing rich in lactic acid bacteria, or lactic acid bacteria fortified health foods or medicines
9.usually use foods containing rich in Bacillus subtilis var. natto (B. natto), or B. natto fortified health foods or medicines
10.usually use medicines, health foods, "Foods for Specified Health Uses (FOSHU)," or "Foods with Functional Claims (FFC)" that may affect bowel movement / take ingredients affecting bowel movement (such as dietary fiber) fortified foods
11.usually use or take other FOSHU or FFC
12.currently taking medications (including herbal medicines) and supplements
13.are allergic to medicines and/or the test food related products
14.are day- and night- shift workers / work night multiple times during this trial
15.plan to go abroad during this trial
16.anthropometric measurements, physical examination values or laboratory values markedly deviate from the reference values at pre-consumption test
17.are pregnant, lactation, or planning to become pregnant during this trial
18.suffer from COVID-19
19.have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial
20.are judged as ineligible to participate in this study by the physician
100
1st name | Tsuyoshi |
Middle name | |
Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
1st name | Naoko |
Middle name | |
Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
03-3818-0610
nao@orthomedico.jp
ORTHOMEDICO Inc.
KAMEDA SEIKA CO., LTD.
Profit organization
Medical Corporation Seishinkai, Takara Clinic
Nerima Medical Association, Minami-machi Clinic
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
2023 | Year | 11 | Month | 28 | Day |
Unpublished
Terminated
2022 | Year | 07 | Month | 20 | Day |
2022 | Year | 07 | Month | 20 | Day |
2022 | Year | 07 | Month | 28 | Day |
2022 | Year | 11 | Month | 28 | Day |
2022 | Year | 07 | Month | 25 | Day |
2023 | Year | 11 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055216